Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 11
Abstract
[Objective] To investigate the efficacy and safety of sofosbuvir/velpatasivr/voxilaprevir （SOF/VEL/VOX） in patients with HCV infection experiencing failure in previous direct-acting antiviral agent （DAA） therapy. [Methods] A retrospective analysis was performed for the chronic hepatitis C patients who experienced failure in previous DAA antiviral therapy and were treated with SOF/VEL/VOX （400 mg/100 mg/100 mg/tablet， 1 tablet/day） for 12 weeks in Nanjing Second Hospital， Wuxi Fifth People’s Hospital， and The Third People’s Hospital of Zhenjiang from June 2020 to June 2023. Sustained virological response at 12 weeks （SVR12） was observed after the end of treatment， and the changes in biochemical parameters and the incidence rate of adverse reactions were assessed to evaluate drug safety. The paired t-test was used for comparison of continuous data between two groups. [Results] A total of 36 patients were enrolled， among whom there were 27 non-liver cirrhosis patients and 9 patients with compensated liver cirrhosis， and 4 patients experienced failure in the previous two or more sessions of DAA therapy. Two patients were lost to follow-up after treatment， and the remaining 34 patients （34/36， 94.4%） achieved SVR12. Among the 36 patients enrolled， the most common adverse events were pruritus， nausea， fatigue， and headache， and one patient （2.78%） experienced serious adverse events； there were no adverse events that resulted in the discontinuation of therapeutic agents or the death of patients. [Conclusion] For chronic hepatitis C patients who experience failure in previous DAA therapy， SOF/VEL/VOX salvage therapy has a relatively high rate of SVR12， with good tolerability and safety.
Authors and Affiliations
Mengying ZHU, Ping YU, Guohong GE, Yuqi MA, Xiling FU, Jiabao CHANG
Keywords
Related Articles
- EP ID EP753493
- DOI 10.12449/JCH241112
- Views 20
- Downloads 1
Advances and thoughts in the diagnosis and treatment of pancreatic cancer
In recent years， significant progress has been made in the standardized diagnosis and treatment of pancreatic cancer in China. From the lack of treatment options and poor drug efficacy at the beginning to the current co...
Mechanism of 1，25（OH）2D3 improving liver inflammation in a rat model of nonalcoholic steatohepatitis induced by choline-deficient L-amino acid-defined diet
[Objective] To investigate the effect of 1，25（OH）2D3 on the level of peroxisome proliferator-activated receptor-γ （PPAR-γ） in the liver， the phenotype of hepatic macrophages， and liver inflammation in a rat model...
Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatotic liver disease is the largest liver disease around the world and is a serious public health hazard， but there has always been a lack of drugs approved for treatment. On March 14...
Growth retardation and hepatopathy associated with single heterozygous mutations in the IARS1 gene： A case report
Mutations in the IARS1 gene are rare in clinical practice， and up to now， only ten cases with detailed clinical and genetic data have been recorded in the literature. This article reports a case of growth retardation，...
Value of Δtotal bilirubin-alpha-fetoprotein scoring model in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure
[Objective] To investigate the association of the dynamic changes of serum total bilirubin （ΔTBil） and alpha-fetoprotein （AFP） with the short-term prognosis of patients with hepatitis B virus-associated acute-on-chro...